Glenmark Pharma launches antidiabetic injectable

January 3, 2024
Posted by: AliensFaith
Category: OBJECTIVE PRESS

Glenmark Pharmaceuticals has launched the first biosimilar of the popular anti-diabetic drug, Liraglutide in India. The drug, marketed as Lirafit, is an injectable anti-diabetic medication that lowers therapy cost by 70%. It has received approval from the Drug Controller General of India and is priced at approximately Rs 100 for a standard dose of 1.2 mg per day. This launch marks Glenmark’s entry into the injectable anti-diabetic market, expanding their presence in the diabetes therapy space.

Author: AliensFaith

HighTech FinTech researcher, university lecturer & Scholar. He is studying his second doctoral degree at the Hague International University. Studying different fields of Sciences gave him a broad understanding of various aspects of life. His recent researches covered AI, Machine-learning & Automation concepts. The Information Technology Skills & Knowledge gave his company a higher position over other regional high-tech consultancy services. The other qualities and activities which can describe him are a Hobbyist Programmer, Achiever, Strategic Thinker, Futuristic person, and Frequent Traveler.

how can we help you?

Glenmark Pharma launches antidiabetic injectable

Share this:

Share this:

Discover more from Maheri Network